CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 263 enrolled
Drug / intervention
Marijuana +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01964404
NCT01964404Phase 1Completed
CompareCT.gov

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

Dartmouth-Hitchcock Medical Center·interventional·Posted Oct 17, 2013·Updated Dec 9, 2025

In Brief

A Phase 1 clinical trial evaluating Marijuana, Dronabinol, and 1 other intervention for Schizophrenia and 3 related conditions. Completed, enrolled 263 participants across 2 sites.

Detailed Summary

In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring cannabis use disorder, will in fact ameliorate the brain reward circuit dysregulation in these patients and, thereby, provide evidence in support of the role of cannabis as a "self-medication" agent for them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
CountriesUnited States
CollaboratorsColumbia University, Harvard Medical School (HMS and HSDM), Massachusetts Institute of Technology, Massachusetts General Hospital, Nathan Kline Institute for Psychiatric Research, University of Vermont, National Institute on Drug Abuse (NIDA)

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 17, 2013
Enrollment StartJul 1, 2014
Primary CompletionSep 18, 2021
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 12.7 years ago

Interventions

Marijuanadrug

Smoked plant with THC

Dronabinoldrug

Capsule with THC

Placebodrug

Capsule with no active ingredient